How an ayurvedic OTC brand ran Growth-tier ChatGPT Ads with AYUSH-clean creative in the immunity-supplement bucket
The situation
Picture a mid-sized ayurvedic OTC brand with a handful of immunity-focused SKUs — a classical formulation tablet, a proprietary immunity syrup, and a chyawanprash-adjacent product — sold both through general trade and its own D2C site, the kind of brand that had spent years building distribution credibility but had never run a paid conversational channel with any discipline. Its existing Google Shopping and Meta spend converted reasonably on brand-search terms but did almost nothing to capture the much larger volume of people asking general wellness assistants about immunity support, seasonal illness prevention, or "natural alternatives" during cold-and-flu season, because none of that conversational volume showed up in a keyword-bid interface built around search terms rather than conversations.
The brand's category problem was sharper than a generic wellness brand's: ayurvedic OTC advertising sits under AYUSH Ministry guidelines in addition to the ASCI and DCGI frameworks that apply to any healthcare-adjacent product, and the brand's own marketing team, capable as it was on packaging and retail activation, had no in-house process for screening conversational ad copy against AYUSH's specific restrictions on disease-cure language before it ever reached the broader compliance question of whether the copy was misleading under ASCI. Two previous attempts at paid digital, run through generalist agencies, had produced ad copy that technically avoided outright disease-cure claims but used phrasing close enough to implied treatment efficacy that the brand's own legal counsel had flagged it after the fact — a pattern the brand wanted to avoid repeating with a new channel.
A third dimension shaped the brief: the brand's genuine differentiator was formulation heritage and AYUSH licensing rather than price, and its own customer research showed that people asking conversational assistants about ayurvedic immunity products were often comparing traditional-use credibility across brands rather than comparing price per unit, meaning the campaign's real job was to win the trust conversation, not the discount conversation, an emphasis that shaped everything from bid ladder design to landing-page content.
The ChatGPT Ads campaign structure ICG designed
Growth-tier's two-to-three-bucket structure fit this account cleanly: a general immunity-education bucket capturing broad "how to boost immunity naturally" and seasonal-illness-prevention conversations, and a purchase-intent bucket capturing conversations where a user had already named a product category — chyawanprash, immunity tablets, ayurvedic syrup — and was comparing options or asking where to buy. A third, smaller bucket ran specifically around AYUSH-credential and formulation-heritage conversations, since a meaningful share of users asked assistants directly about licensing, ingredient sourcing, or how a proprietary formulation differed from a classical one, questions that needed their own landing content rather than being folded into general purchase-intent.
Bid ladder design kept the education bucket's bids conservative, since that conversation stage was explicitly a brand-trust and top-of-funnel play rather than a conversion play, while the purchase-intent bucket carried bids in the 4-6x range above the education baseline for conversations where a user asked for a specific product recommendation or asked where to purchase. Within purchase-intent, conversations that referenced a specific competitor category term — "instead of allopathic cold medicine" or similar comparative framing — were flagged for compliance review before any ad response was permitted to engage, since that framing sits closest to the line AYUSH and ASCI both restrict around comparative or replacement claims against conventional medicine.
Landing infrastructure ran three pages matched to the three buckets: an educational immunity-support page citing traditional-use ingredients without disease-cure framing, a product-comparison page for purchase-intent conversations that named the brand's SKUs against generic category attributes rather than named competitors, and a formulation-and-licensing page for the credential-focused bucket, listing AYUSH registration details and manufacturing certification in a format built to be machine-scannable by conversational assistants pulling structured facts rather than marketing prose. Each page carried the brand's AYUSH licence number and GMP certification visibly, both because it mattered for trust and because ICG's experience across the ayurvedic OTC segment shows conversational assistants weight verifiable licensing detail meaningfully when synthesising a recommendation.
Conversion tracking on the D2C purchase path ran through the same conversation-completion attribution as the rest of ICG's ChatGPT Ads accounts, with a secondary event captured for sample-request or retailer-locator conversions for users not ready to purchase online directly — a meaningful share of this brand's actual customers, given how much ayurvedic OTC purchasing in India still happens through a trusted local chemist rather than D2C checkout, and the retailer-locator conversion gave the brand a way to credit the channel for driving that offline path too.
The compliance discipline
AYUSH Ministry advertising guidelines formed the first and strictest screen on every ad variant, ahead of the broader ASCI and NMC review that applies across ICG's healthcare book. No copy across any of the three buckets claimed the product prevented, treated or cured any named disease or infection — immunity language stayed at "supports" and "traditionally used for," language grounded in classical ayurvedic texts and formulation heritage rather than modern clinical-outcome framing, since AYUSH guidelines specifically distinguish traditional-use description from an implied clinical claim and the account's copy was written to stay clearly on the traditional-use side of that line.
The comparative-claim restriction carried particular weight for this brand because its own prior agency-run copy had drifted close to implying the product as an alternative to allopathic treatment, precisely the framing AYUSH and ASCI both prohibit. Every variant in the purchase-intent bucket was screened specifically for replacement-language — phrasing that positioned the product as something to take instead of prescribed medicine rather than alongside a generally healthy lifestyle — and any variant carrying even indirect replacement framing was rejected before it reached launch, a stricter internal bar than the brand's previous agency had applied.
ASCI Chapter III's general prohibition on misleading efficacy claims applied on top of the AYUSH-specific screen, since a claim can clear AYUSH's traditional-use framing and still run afoul of ASCI if it implies a stronger or faster effect than the product's actual formulation supports — a distinction that mattered for the syrup SKU in particular, where the brand's own marketing instinct leaned toward "fast-acting" language that ICG's compliance review flagged as unsupportable without clinical substantiation the brand didn't have on file. DPDP 2023 governed the sample-request and enquiry forms, since a field asking whether a user had an existing health condition or was taking other medication counts as sensitive health data regardless of the product being OTC, and the form's consent language was written explicitly rather than folded into a generic checkbox.
The 90-day outcome pattern
In the pattern ICG has observed on comparable Growth-tier ayurvedic OTC accounts, the education bucket ramped fastest, since general immunity-support conversations run at meaningfully higher volume than product-specific purchase-intent ones. Illustrative combined conversation-completion events across the three buckets: roughly 60-80 a week in month one, climbing to an illustrative 180-220 a week by month three as the purchase-intent and credential buckets caught up once enough data had classified their intent ladders.
The purchase-intent bucket, despite its lower volume relative to education, carried the strongest conversion economics of the three: illustratively 12-16% of purchase-intent conversations converted to either a D2C purchase or a retailer-locator click within 3 days, against a much lower single-digit conversion rate for the education bucket over the same window, consistent with the expected pattern that a user who has already named a product category converts faster than one still exploring general wellness questions. The credential-and-formulation bucket, the smallest by volume, showed the highest downstream repeat-purchase signal among users who could be tracked back through D2C order history — illustratively 20-25% of that bucket's converters made a second purchase within 60 days, versus 10-15% for purchase-intent-bucket converters, suggesting that users who engage specifically with licensing and heritage content skew toward the brand's most loyalty-prone segment.
Blended cost per qualified conversion — combining D2C purchase and retailer-locator events — ran illustratively 15-20% below the brand's blended Meta Ads cost per conversion over the same quarter, with GA4's AI Assistant channel showing a key-event rate broadly consistent with ICG's wider healthcare-adjacent book. Retailer-locator conversions, which the brand's previous agencies had never tracked at all, turned out to represent a meaningful share — illustratively 30-35% — of total qualified conversions, giving the brand its first real visibility into how much of its conversational ad spend was driving offline chemist-counter purchases rather than online checkout, a finding that reshaped how the brand's own trade marketing team thought about the channel's role.
What we'd do differently next time
Merging the education and purchase-intent buckets for the first two weeks, done originally to simplify launch, meant early compliance review had to screen a wider mix of conversation types under one workflow before the buckets' distinct intent ladders had separated out, slowing initial review turnaround more than necessary. Splitting the two buckets from day one, even with lower initial volume in each, would have let compliance review specialise faster.
The credential-and-formulation bucket's outsized repeat-purchase signal wasn't obvious from month-one data alone, since its absolute conversion volume was too low in the first four weeks to be confident the pattern was real rather than noise. Building a longer minimum observation window — six weeks rather than four — before drawing conclusions about which bucket to prioritise for budget would have avoided the temptation to under-fund the smallest bucket too early based on thin data.
Finally, the brand's own retail team wasn't looped into the retailer-locator conversion data until month two, meaning a full month of insight about which cities were generating the strongest offline-purchase intent went unused for trade activation planning. Building a standing monthly data-share with the retail and trade marketing function from launch, not as an afterthought once the channel was already proving itself, would have let the brand act on geographic demand signal sooner.
How this maps to your own ayurvedic or ayush-adjacent brand
If your ayurvedic or AYUSH-licensed OTC brand runs more than one SKU category or serves both a D2C and general-trade purchase path, this Growth-tier structure — separate education and purchase-intent buckets, a dedicated credential-and-heritage bucket, and AYUSH-clean copy screened before it ever reaches ASCI review — is a reasonable starting shape even at modest initial budgets, since the compliance discipline matters as much at low spend as at high spend.
The core transferable lesson is that ayurvedic OTC advertising compliance is a two-layer problem, not one: AYUSH's traditional-use-versus-disease-claim distinction sits underneath the general ASCI and DPDP layers every healthcare-adjacent brand already has to manage, and a brand that treats AYUSH review as a formality rather than a first-class screen is the brand most likely to have copy flagged after launch rather than before it.
